Ormutivimab

奥木替韦单抗

Report date: 2024/03/01 11:56:35

Base Information

Drug NameOrmutivimab

Drug Alias Name重组人源抗狂犬病毒单抗（华北制药）SOJBAnti-rabies monoclonal antibody (Molecular Targeting Technologies/North China Pharmaceutical Corporation)抗狂犬病单克隆抗体 (Molecular Targeting Technologies/North China Pharmaceutical Corporation)Human anti-rabies mAb (Molecular Targeting Technologies/North China Pharmaceutical Corporation) +[8]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionRabies virus neutralization

TargetsRabies virus

Therapy Area/IndicationsRabies

Global Approved IndicationsRabies

Approved Indications in ChinaRabies

Original Approved Country/TerritoryMainland China

Original Approved Date2022/01/25

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesThomas Jefferson University

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNorth China Pharmaceutical Group New Drug R&D Co Ltd

Inactive CompaniesNcpc Genetech Biotechnology Co Ltd

Active IndicationsRabies

Inactive IndicationsN/A

Other Information

ATC CodeN/A